Linmei Yao

Beijing, 100015, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Efficacy and Safety of Avatrombopag in Patients with Chronic Liver Disease and Thrombocytopenia Undergoing Elective Surgery.

Efficacy and Safety of Avatrombopag in Patients with Chronic Liver Disease and Thrombocytopenia Undergoing Elective Surgery.

Journal: Journal of clinical medicine

Published: June 05, 2026

Precision treatment and frontier advances of glycyrrhizin preparations in drug-induced liver injury (DILI).

Precision treatment and frontier advances of glycyrrhizin preparations in drug-induced liver injury (DILI).

Journal: Frontiers in pharmacology

Published: May 25, 2026

Efficacy of NAs in combination with Peg-IFN for functional cure in patients with CHB: a meta-analysis of RCTs.

Efficacy of NAs in combination with Peg-IFN for functional cure in patients with CHB: a meta-analysis of RCTs.

Journal: Annals of medicine

Published: March 04, 2026

Baseline Liver Fibrosis Severity Predicts Superior HBeAg Clearance and Fibrosis Reversal following Peg-IFNα plus Nucleos(t)ide Analog Therapy in HBeAg-positive Chronic Hepatitis B Patients.

Baseline Liver Fibrosis Severity Predicts Superior HBeAg Clearance and Fibrosis Reversal following Peg-IFNα plus Nucleos(t)ide Analog Therapy in HBeAg-positive Chronic Hepatitis B Patients.

Journal: Journal of clinical and translational hepatology

Published: February 27, 2026

Analysis of risk factors and establishment of a predictive model for liver disease severity in metabolic dysfunction-associated fatty liver disease.

Analysis of risk factors and establishment of a predictive model for liver disease severity in metabolic dysfunction-associated fatty liver disease.

Journal: Frontiers in medicine

Published: February 07, 2026

Glycyrrhizin preparations in liver diseases: a narrative review of mechanisms and therapeutic potential.

Glycyrrhizin preparations in liver diseases: a narrative review of mechanisms and therapeutic potential.

Journal: Frontiers in pharmacology

Published: January 24, 2026

The Application of Nanomaterials in the Detection of Liver Cancer Biomarkers.

The Application of Nanomaterials in the Detection of Liver Cancer Biomarkers.

Journal: International journal of nanomedicine

Published: January 10, 2026

HBsAg loss in chronic hepatitis B patients with an HBsAg decline plateau can be enhanced by intermittent PEG-IFN treatment.

HBsAg loss in chronic hepatitis B patients with an HBsAg decline plateau can be enhanced by intermittent PEG-IFN treatment.

Journal: Frontiers in cellular and infection microbiology

Published: December 30, 2025

The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma.

The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma.

Journal: Clinical and experimental medicine

Published: August 26, 2025

COVID-19 Infection, Drugs, and Liver Injury.

COVID-19 Infection, Drugs, and Liver Injury.

Journal: Journal of clinical medicine

Published: July 28, 2025

Association between changes in HBsAb levels and hepatic adverse events after HBsAg clearance in non-cirrhotic chronic hepatitis B patients.

Association between changes in HBsAb levels and hepatic adverse events after HBsAg clearance in non-cirrhotic chronic hepatitis B patients.

Journal: BMC infectious diseases

Published: July 13, 2025

Progress in the Application of Nanobiotechnology in the Ablation Therapy of Hepatic Carcinoma.

Progress in the Application of Nanobiotechnology in the Ablation Therapy of Hepatic Carcinoma.

Journal: International journal of nanomedicine

Published: July 07, 2025

Showing 1-12 of 19

Last Updated: 09/26/2026